Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313160841> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4313160841 abstract "<h3>Introduction/Background</h3> Ovarian cancer (OC) is the eighth leading cause of cancer in women worldwide, with high mortality due to the advanced stage at which it is diagnosed. Neoadjuvant chemotherapy is a treatment option in patients who are not candidates for primary surgery. HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is a treatment option during interval laparotomy. Our objective is to present the patterns of recurrence between patients treated with chemotherapy and interval surgery and those who underwent HIPEC, within an institutional protocol. <h3>Methodology</h3> The review of 33 patients who were treated between 2016–2022 was carried out, 17 of them underwent HIPEC during interval laparotomy. Demographic variables and sites of recurrence, as well as disease status, were analyzed. <h3>Results</h3> During a median follow-up of 36 months, from 16 cases in the non-HIPEC group, there were 8 recurrences (50%): 2 systemic (lung, liver), 1 in the groin, 2 in the perigastric nodes, 1 peritoneal, and 1 in the gastric wall; while in the HIPEC group, 6 patients (35.3%) recurred: 3 systemic, 1 in a pelvic node and 2 in peritoneum. In the non-HIPEC group, there were 6 (37.5%) deaths, 4 (25%) patients are alive with disease, and 6 alive without evidence of disease. In the HIPEC group, 5 (29.4%) patients died, 3 (17.6%) are alive with disease, and 9 (52.9%) are alive without disease. <h3>Conclusion</h3> Various patterns of recurrence have been reported in patients after interval surgery, being the peritoneum and abdominopelvic lymph nodes the most frequent sites; and post-HIPEC recurrence are most common in visceral tissues. In our series, the recurrences are highly variable in the non-HIPEC group, with systemic disease being the most common; in the HIPEC group, systemic recurrences are more alike with usual patterns in OC, however, the peritoneum continues to be a point of relapse despite the HIPEC." @default.
- W4313160841 created "2023-01-06" @default.
- W4313160841 creator A5006542895 @default.
- W4313160841 creator A5017575942 @default.
- W4313160841 creator A5034364815 @default.
- W4313160841 creator A5077288132 @default.
- W4313160841 date "2022-10-01" @default.
- W4313160841 modified "2023-10-18" @default.
- W4313160841 title "2022-RA-1654-ESGO Recurrence patterns in patients with ovarian cancerafter neoadjuvant chemotherapy, with and without HIPEC. Report of 33 first cases" @default.
- W4313160841 doi "https://doi.org/10.1136/ijgc-2022-esgo.766" @default.
- W4313160841 hasPublicationYear "2022" @default.
- W4313160841 type Work @default.
- W4313160841 citedByCount "0" @default.
- W4313160841 crossrefType "proceedings-article" @default.
- W4313160841 hasAuthorship W4313160841A5006542895 @default.
- W4313160841 hasAuthorship W4313160841A5017575942 @default.
- W4313160841 hasAuthorship W4313160841A5034364815 @default.
- W4313160841 hasAuthorship W4313160841A5077288132 @default.
- W4313160841 hasBestOaLocation W43131608411 @default.
- W4313160841 hasConcept C121608353 @default.
- W4313160841 hasConcept C126322002 @default.
- W4313160841 hasConcept C141071460 @default.
- W4313160841 hasConcept C146357865 @default.
- W4313160841 hasConcept C151730666 @default.
- W4313160841 hasConcept C2776694085 @default.
- W4313160841 hasConcept C2779458272 @default.
- W4313160841 hasConcept C2780427987 @default.
- W4313160841 hasConcept C2780778865 @default.
- W4313160841 hasConcept C2994223192 @default.
- W4313160841 hasConcept C71924100 @default.
- W4313160841 hasConcept C86803240 @default.
- W4313160841 hasConceptScore W4313160841C121608353 @default.
- W4313160841 hasConceptScore W4313160841C126322002 @default.
- W4313160841 hasConceptScore W4313160841C141071460 @default.
- W4313160841 hasConceptScore W4313160841C146357865 @default.
- W4313160841 hasConceptScore W4313160841C151730666 @default.
- W4313160841 hasConceptScore W4313160841C2776694085 @default.
- W4313160841 hasConceptScore W4313160841C2779458272 @default.
- W4313160841 hasConceptScore W4313160841C2780427987 @default.
- W4313160841 hasConceptScore W4313160841C2780778865 @default.
- W4313160841 hasConceptScore W4313160841C2994223192 @default.
- W4313160841 hasConceptScore W4313160841C71924100 @default.
- W4313160841 hasConceptScore W4313160841C86803240 @default.
- W4313160841 hasLocation W43131608411 @default.
- W4313160841 hasOpenAccess W4313160841 @default.
- W4313160841 hasPrimaryLocation W43131608411 @default.
- W4313160841 hasRelatedWork W167319750 @default.
- W4313160841 hasRelatedWork W1964215666 @default.
- W4313160841 hasRelatedWork W2008064506 @default.
- W4313160841 hasRelatedWork W2067366728 @default.
- W4313160841 hasRelatedWork W2375159187 @default.
- W4313160841 hasRelatedWork W2390961722 @default.
- W4313160841 hasRelatedWork W2417262672 @default.
- W4313160841 hasRelatedWork W2422477887 @default.
- W4313160841 hasRelatedWork W2423650732 @default.
- W4313160841 hasRelatedWork W4250083105 @default.
- W4313160841 isParatext "false" @default.
- W4313160841 isRetracted "false" @default.
- W4313160841 workType "article" @default.